Sign up USA
Proactive Investors - Run By Investors For Investors

Edgewater Technology acquires Oracle specialist

Edgewater Technology has acquired the assets of Oracle database software specialist M2 Dynamics.
Edgewater Technology acquires Oracle specialist
The acquisition was welcomed by Oracle

Edgewater Technology (NASDAQ:EDGW) has acquired the assets of Oracle database software specialist M2 Dynamics.

Edgewater, a consulting firm, said M2 would join its Edgewater Ranzal unit in providing clients with information technology (IT) services, specializing in business analytics, encompassing enterprise performance management (EPM) and so-called Big Data.

“We have been working on the M2 transaction for several months and are pleased to complete this highly complementary acquisition. The acquisition of this key Oracle EPM asset represents another important step in our strategy to provide the full range and breadth of service delivery that our customers are demanding,” said Shirley Singleton, Edgewater's chairman, president and chief executive officer (CEO).

The company expects the acquisition to enhance earnings per share in 2016.

“We are pleased to see Edgewater Ranzal and M2 come together,” said Hari Sankar, group vice president of product management at Oracle.

“The combination will provide depth of expertise covering the full range of enterprise performance management offerings across Cloud and on-premises, and deliver value for Oracle customers,” Sankar added.

John-H.jpg


Register here to be notified of future INDU Company articles
View full INDU profile

US Market News Timeline

Newswire
August 05 2016

Related Articles

shutterstock_152199281_56fd078fe84f7.jpg
March 31 2016
Amryt Pharmaceuticals is coming to the market following a reverse takeover deal with the investment firm Fastnet Equities. Here boss Joseph Wiley tells us a little bit more about the AIM newcomer.
sareum-test-tubes.png
March 10 2016
November saw the Finland-based life sciences firm list on the London Exchange, raising €14.2mln.
Heart-cells.jpg
April 13 2016
Jim Phillips, Midatech’s chief executive, said Zuplenz offers relief from some of the most debilitating side-effects of common cancer treatments. Generically called ondansetron, the oral soluble film eases the problem of gritty residue, having to wear a patch and sedative side effects of dissolving tablets and injections.
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC